Caristo Congratulates Abcentra for First Patient Dosed Successfully in Phase 2b 'FORTIFY' Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

CARISTO-DIAGNOSTICS

More Like This

PR Newswire associated0

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Caristo Diagnostics to Highlight New Findings Reinforcing the Science of Its Coronary Inflammation and Plaque Analysis Technologies at SCCT 2026

PR Newswire associated0

Caristo to Unveil New Clinical and Research Results at SCCT 2025

PR Newswire associated0

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

PR Newswire associated0

New Data at ESC Congress 2026 Validate Caristo's FAI-Score™ Biomarker and Highlight Potential Non-Contrast Cardiac CT Opportunity

PR Newswire associated0

Caristo's Technology to be Featured in Non-Contrast CT and Late-Breaking Stroke Prediction Data at ESC 2026

PR Newswire associated0

Caristo Secures FDA Clearance, Ushering in a New Era of AI-Powered Heart Attack Prevention

PR Newswire associated0

Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention